Forex
Roche Shares Slip Amid Consolidation Phase
Roche Holding AG Participation shares took a hit on August 24, 2026, falling by 1.4% to CHF 370.5 after a prolonged rally that saw the stock jump over 46% from its 52-week low of CHF 252.2.
The decline reflects a broader consolidation phase that has been building since Roche's H1 2026 results showed 6% constant-currency sales growth but a 2% decline in reported Swiss franc terms, due to the strong franc's drag on top line revenue.
A $750 million U.S. manufacturing investment by Roche's Genentech subsidiary, announced earlier in the week, has also weighed on investor sentiment, with some analysts flagging near-term cost implications of the outlay.